ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

ProKidney (Nasdaq: PROK) announced that CEO Bruce Culleton, M.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 8:15am PST.

The management team will host one-on-one meetings during the event. A live webcast will be available via the company’s Investor Relations "Events" page and at www.prokidney.com. A replay will be accessible for 30 days after the presentation.

News Market Reaction – PROK

+5.14%

30 alerts

+5.14% Session close to close

+12.2% Peak in 28 hr 54 min

$762.62M Market Cap

0.9x Rel. Volume

In the Jan 6 session, PROK gained 5.14%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.2% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.1% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +5.1% in the session following this news. A strong positive reaction aligns with prior instances where clinical and conference-related news coincided with gains, such as moves of 4.07%, 4.62%, and 10.77% after past updates. However, the negative 6.57% move following Q3 earnings shows sentiment can shift quickly. Investors watching this type of conference appearance might weigh it against the company’s cash position, late-stage trial timelines, and previous volatility when assessing durability of any upside.

Key Figures

Conference edition: 44th Presentation date: January 14, 2026 Presentation time: 8:15am PST +1 more

4 metrics

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Presentation date January 14, 2026 Scheduled company presentation at J.P. Morgan conference

Presentation time 8:15am PST Scheduled time for conference presentation

Replay period 30 days Duration webcast replay will be available

Historical Context

5 past events · Latest: Nov 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 10	Earnings & updates	Positive	-6.6%	Q3 2025 financials plus regulatory and clinical progress updates.
Nov 06	Clinical data	Positive	+4.1%	Full Phase 2 REGEN-007 results showing slowed CKD progression.
Oct 29	Conference participation	Neutral	+2.0%	Announcement of participation in Guggenheim and Jefferies conferences.
Oct 20	Scientific abstracts	Positive	+10.8%	Two abstracts selected for ASN Kidney Week 2025 presentations.
Aug 27	Conference participation	Neutral	+4.6%	Planned presentations at Citi and Morgan Stanley healthcare conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news on clinical data and conferences generally coincided with positive price reactions, while the Q3 earnings and update event saw a negative move.

Recent Company History

Over the last several months, ProKidney reported Q3 2025 results with $271.7M in cash and marketable securities and reaffirmed progress toward a Phase 3 accelerated approval readout expected in Q2 2027. Multiple announcements highlighted positive Phase 2 REGEN-007 data and growing conference visibility, including Guggenheim, Jefferies, Citi, and Morgan Stanley events. Those items often coincided with positive share moves. The new J.P. Morgan Healthcare Conference appearance continues this pattern of active investor and scientific engagement.

Key Terms

cell therapy, chronic kidney disease, webcast

3 terms

cell therapy medical

"a leading late clinical-stage cell therapy company focused on chronic kidney"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

chronic kidney disease medical

"cell therapy company focused on chronic kidney disease (CKD), today announced"

Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.

webcast technical

"Format: PresentationWebcast: Link The live webcast will also be accessible"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44^th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.

44^th Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 14, 2026
Time: 8:15am PST
Format: Presentation
Webcast: Link

The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the event, a replay will be available for 30 days.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com

Media Contact
Audra Friis
audrafriis@sambrown.com

Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com

FAQ

When will ProKidney (PROK) present at the J.P. Morgan Healthcare Conference?

ProKidney will present on January 14, 2026 at 8:15am PST.

Who from ProKidney will present at the conference for PROK?

CEO Bruce Culleton, M.D. will present on behalf of ProKidney.

How can investors watch ProKidney's (PROK) presentation on January 14, 2026?

A live webcast will be available via ProKidney's Investor Relations "Events" page and at www.prokidney.com.

Will ProKidney (PROK) make the presentation replay available after the event?

Yes. A replay will be available for 30 days following the presentation.

Will ProKidney management hold investor meetings at the 2026 J.P. Morgan Healthcare Conference?

Yes. The ProKidney management team will host one-on-one meetings throughout the event.

What format will ProKidney's (PROK) J.P. Morgan presentation use on January 14, 2026?

The presentation will be a live webcast beginning at 8:15am PST with management available for one-on-one meetings.